• The Journal of Internal Korean Medicine
• /
• v.43 no.1
• /
• pp.22-40
• /
• 2022

Objectives: The purpose of this study is to assess the antidiabetic effect and safety of Galgunhwangryunhwanggum-tang for type 2 diabetes without complications by analyzing related research. Methods: For a systematic review and meta-analysis, we searched for the antidiabetic effect and safety of Galgunhwangryunhwanggum-tang for type 2 diabetes without complications in 10 databases up to September 2021. Only randomized controlled trials were chosen. Results: In the treatment effectiveness analysis and meta-analysis, Galgunhwangryunhwanggum-tang had significant improvement effects on fasting plasma glucose level, 2-hour postprandial glucose level, glycated hemoglobin, fasting insulin, and homeostasis model assessment for insulin resistance compared to the control group when treated in parallel with oral glycemic drugs. Conclusion: Galgunhwangryunhwanggum-tang is effective in improving blood sugar and insulin resistance in type 2 diabetes patients without complications and can especially be considered in parallel treatment with oral hypoglycemic drugs. A large-scale randomized controlled clinical trial is required to complement the limitations presented in this study in the future.

• Korean Journal of Clinical Laboratory Science
• /
• v.51 no.4
• /
• pp.504-513
• /
• 2019

The purpose of this study was to determine the antidiabetic and antioxidative effects of Bitter melon on streptozotocin-induced diabetic rats. The normal and the control groups were fed an AIG -93M diet, and the Bitter melon groups were fed 1%, 2% and 3% Bitter melon powder. After two weeks, the control and the experimental group were induced to a diabetic state with the administration of streptozotocin. The blood glucose control and antioxidant activity were analyzed after the animals were sacrificed. The blood glucose levels of all the Bitter melon groups were lower than those of the control group, and the 2% Bitter melon group showed significantly lower blood glucose levels than those of the control group. Serum Triglyceride and HDL-cholesterol of the 2%, and 3% Bitter melon groups were significantly lower than those of the control group. The total cholesterol levels of the bitter melon groups were significantly lower than those of the control group. The serum insulin levels of the induced groups were significantly lower than those of the normal group. The HbA1c levels of the 2% and 3% Bitter melon groups were significantly lower than those of the control group. For the level of antioxidant enzymes in the liver tissues, the 2% Bitter melon group was significantly higher than that of the control group. These results show the antidiabetic and antioxidative effects of Bitter melon for the prevention and treatment of diabetes.

• Journal of Nutrition and Health
• /
• v.47 no.3
• /
• pp.167-175
• /
• 2014

Purpose: Previous studies have shown that treatment with Smilax china L. leaf extract (SCLE) produces antidiabetic effects due to ${\alpha}$-glucosidase inhibition. In this study, we examined the mechanism underlying these antidiabetic effects by examining glucose uptake in HepG2 cells cultured with SCLE. Methods: Glucose uptake and glucokinase activity were examined using an assay kit. Expression of glucose transporter (GLUT)-2, GLUT-4, and HNF-$1{\alpha}$ was measured by RT-PCR or western blot. Results: Treatment with SCLE resulted in enhanced glucose uptake in HepG2 cells, and this effect was especially pronounced when cells were cultured in an insulin-free medium. SCLE induced an increase in expression of GLUT-2 but not GLUT-4. The increase in the levels of HNF-$1{\alpha}$, a GLUT-2 transcription factor, in total protein extract and nuclear fraction suggest that the effects of SCLE may occur at the level of GLUT-2 transcription. In addition, by measuring the change in glucokinase activity following SCLE treatment, we confirmed that SCLE stimulates glucose utilization by direct activation of this enzyme. Conclusion: These results demonstrate that the potential antidiabetic activity of SCLE is due at least in part to stimulation of glucose uptake and an increase in glucokinase activity, and that SCLE-stimulated glucose uptake is mediated through enhancement of GLUT-2 expression by inducing expression of its transcription factor, HNF-$1{\alpha}$.

• Journal of Korean Medicine for Obesity Research
• /
• v.20 no.2
• /
• pp.69-77
• /
• 2020

Objectives: In this study, we investigated the antiobesity and antidiabetic effects of polyherbal extract, DM2 consisting of Atractylodis Rhizoma, Anemarrhenae Rhizoma, Cinnamomi Cortex, and Moutan Radicles Cortex in high fat diet-induced obesity mice. Methods: DM2 extract was prepared with a hot water. Six-week-old male C57BL/6N mice were fed a high-fat diet (HFD) for 8 weeks and then administrated with DM2 extract (500 mg/kg, p.o.) for 4 weeks. The changes of physiological markers, body weight (BW), food and water intakes, and the levels of fasting blood glucose (FBG) were measured once a week for 4 weeks in mice. The the serum levels of glucose, insulin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (T-CHO), triglyceride, and low density lipoprotein cholesterol in sera were measured in mice using autometic chemical analyzer and enzyme linked immunosorbant assay. We also observed the histological changes of liver and pancreatic tissues with Hematoxylin & Eosin staining. Results: In physiological change, the increases of BW, calorie intake, and FBG in HFD-induced obese mice were significantly decreased after administration of DM2 extract for 4 weeks. The decrease of water intake was significantly increased in DM2 extract-administrated mice. In serological change, the administration of DM2 extract in obesity mice was significantly decreased the serum levels of glucose, insulin, T-CHO, AST, and ALT levels. We also found that DM2 extract inhibited the increase of lipid droplets in liver and the structural destruction of pancreatic tissues in obesity mice. Conclusion: Our study demonstrated that DM2 extract has antiobesity antidiabetic effects with body weight loss, decrease of glucose and insulin levels, and lipid accumulation on liver tissue.

• Korean Journal of Food Science and Technology
• /
• v.54 no.4
• /
• pp.391-397
• /
• 2022

This study aimed to verify the antidiabetic effects of the unripe black raspberry extract (UBRE) in obese diabetic mice. For the experiment, animal model mice were divided into six groups: normal control, diabetic control, three experimental groups (treated with 75, 150, and 300 mg/kg single dose of UBRE), and a positive control (200 mg/kg metformin). The groups treated with 300 mg/kg UBRE and metformin had significantly reduced blood glucose and triglyceride levels in the diabetic mice compared to those in the vehicle control group. In addition, histopathological evaluation showed that UBRE increased the Langerhans area, cell number, and insulin concentration in the pancreatic islets of db/db mice. Therefore, UBRE exerts significant antidiabetic effects by decreasing the blood glucose and lipid levels, suggesting that it can be consumed as a functional diet for diabetic patients.

• Mass Spectrometry Letters
• /
• v.6 no.2
• /
• pp.48-51
• /
• 2015

Kinsenoside is a principle bioactive compound of Anoectochilus formosanus. It exhibits various pharmacological effects such as antihyperglycemic, antioxidant, anti-inflammatory, immunostimulating, and hepatoprotective activities and has recently been developed as an antidiabetic drug candidate. In this study, as part of an in vitro pharmacokinetic study, the stability of kinsenoside in rat and human liver microsomes was evaluated. Kinsenoside was found to have good metabolic stability in both rat and human liver microsomes. These results will provide useful information for further in vivo pharmacokinetic and metabolism studies.

• Advances in Traditional Medicine
• /
• v.3 no.2
• /
• pp.84-89
• /
• 2003

The antidiabetic efficacy of Enicostemma littorale Blume (chhota chirayata) aqueous extract was examined in newly diagnosed non-insulin-dependent diabetes mellitus (NIDDM) patients taking only the extract and was administered as two divided doses, half an hour before meal as 5g of aqueous extract per single dose. Out of the 20 patients volunteered, 11 successfully completed the 2 month trial and a significant decrease in fasting & postprandial blood glucose and glycosylated haemoglobin levels were observed along with a significant improvement in the antioxidant parameters of the patients. There was also a significant increase in serum insulin levels in 7 patients after extract treatment as compared to levels before treatment. Serum total cholesterol and serum triglyceride levels were decreased significantly with a significant increase in serum HDLCholesterol levels. Other vital parameters remained stable and no side effects were observed. This is the first report showing the hypoglycemic, antioxidant and hypolipidemic properties of the aqueous extract of E. littorale Blume in non-insulin dependent diabetes mellitus patients.

• Journal of Applied Biological Chemistry
• /
• v.49 no.3
• /
• pp.82-85
• /
• 2006

Eucommia ulmoides bark extracts by cold water, boiling water, 100% EtOH, 70% EtOH, 100% MeOH, 70% MeOH and $CHCl_3$ were assayed for their medicinal effects. The antioxidant activity of the extracts ranged from $IC_{50}$ 125.2 to $IC_{50}\;872.7{\mu}g/ml$ in the 1,1-diphenyl-2-picrylhydrazyl (DDPH) free radical-scavenging assay, and cold water extracts had the highest antioxidant activity. $CHCl_3$ extracts had the highest inhibitory effect on angiotensin I-converting enzyme (ACE) giving inhibition of up to 56.4% at a concentration of 1 mg/ml. Extracts in 100% EtOH had the greatest inhibitory effect on $\acute{a}-amylase$ activity ($IC_{50}=174.6{\mu}g/ml$), and 70% MeOH extracts had the greatest inhibitory effect on ${\alpha}-glucosidase$ activity ($IC_{50}=14.0{\mu}g/ml$). Taken together, these results provided the in vitro evidence on the ACE, amylase and glucosidase inhibitory actions of E. ulmoides bark that form the pharmacological basis for its antihypertensive and antidiabetic action.

• Archives of Pharmacal Research
• /
• v.27 no.7
• /
• pp.790-796
• /
• 2004

Ginseng is a shade-loving perennial herb that is cultivated mainly in Korea, Japan, and China. The ginseng root has been used as a tonic remedy, and its antidiabetic activity has been demonstrated as early as 1920s. Although wild ginseng was anecdotally thought to be superior to cultivated ginseng as far as pharmacological properties were concerned, there have been no prior reports on the antidiabetic effect of wild ginseng. In this study, we investigated the preventative anti-diabetic and anti-obese effects of wild ginseng ethanol extract (WGEE). In the preventive experiment, WGEE co-administered with a high fat diet significantly inhibited body weight gain, fasting blood glucose, triglyceride, and free fatty acid levels in a dose dependent manner. WGEE-treated mice at doses of 250 and 500 mg/kg improved the insulin resistance index by 55％ and 61％ compared to the high fat diet (HFD) control, respectively. Diameters of white and brown adipocytes were also decreased by 62％ and 46％ in the WG500-treated group compared to those in HFD fed control mice. Taken together, WGEE has potential as a preventive agent for type 2 diabetes mellitus (and possibly obesity) and deserves clinical trial in the near future.

• Biomolecules & Therapeutics
• /
• v.29 no.2
• /
• pp.154-165
• /
• 2021

This study aimed to investigate whether the antidiabetic drugs dipeptidyl peptidase 4 (DPP4) inhibitors such as evogliptin and sitagliptin affect the membrane DPP4 (mDPP4) enzymatic activity and immune function of T helper1 (Th1) cells in terms of cytokine expression and cell profiles. The mDPP4 enzymatic activity, cytokine expression, and cell profiles, including cell counts, cell viability, DNA synthesis, and apoptosis, were measured in pokeweed mitogen (PWM)-activated CD4+CD26+ H9 Th1 cells with or without the DPP4 inhibitors, evogliptin and sitagliptin. PWM treatment alone strongly stimulated the expression of mDPP4 and cytokines such as interleukin (IL)-2, IL-10, tumor necrosis factor-alpha, interferon-gamma, IL-13, and granulocyte-macrophage colony stimulating factor in the CD4+CD26+ H9 Th1 cells. Evogliptin or sitagliptin treatment potently inhibited mDPP4 activity in a dose-dependent manner but did not affect either the cytokine profile or cell viability in PWM-activated CD4+CD26+ H9 Th1 cells. These results suggest that, following immune stimulation, Th1 cell signaling pathways for cytokine expression function normally after treatment with evogliptin or sitagliptin, which efficiently inhibit mDPP4 enzymatic activity in Th1 cells.